The European LeukemiaNet: Achievements and Perspectives

The only way to cure leukemia is by cooperative research. To optimize research, the European LeukemiaNet integrates 105 national leukemia trial groups and networks, 105 interdisciplinary partner groups and about 1,000 leukemia specialists from 175 institutions. They care for tens of thousands of leukemia patients in 33 countries across Europe. Their ultimate goal is to cure leukemia. Since its inception in 2002, the European LeukemiaNet has steadily expanded and has unified leukemia research across Europe. The European LeukemiaNet grew from two major roots: 1) the German Competence Network on Acute and Chronic Leukemias; and 2) the collaboration of European Investigators on Chronic Myeloid Leukemia. The European LeukemiaNet has improved leukemia research and management across Europe. Its concept has led to funding by the European Commission as a network of excellence. Other sources (European Science Foundation; European LeukemiaNet-Foundation) will take over when the support of the European Commission ends.

Citing Articles

Differential Analysis of Genetic, Epigenetic, and Cytogenetic Abnormalities in AML.

Islam M, Mohamed Z, Assenov Y Int J Genomics. 2017; 2017:2913648.

PMID: 28713819 PMC: 5496127. DOI: 10.1155/2017/2913648.

The European Hematology Association Roadmap for European Hematology Research: a consensus document.

Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Dohner H Haematologica. 2016; 101(2):115-208.

PMID: 26819058 PMC: 4938336. DOI: 10.3324/haematol.2015.136739.

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

Cross N, White H, Colomer D, Ehrencrona H, Foroni L, Gottardi E Leukemia. 2015; 29(5):999-1003.

PMID: 25652737 PMC: 4430701. DOI: 10.1038/leu.2015.29.

A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality.

Labopin M, Gorin N, Polge E, Socie G, Gurman G, Gluckman E Bone Marrow Transplant. 2013; 49(3):376-81.

PMID: 24241579 DOI: 10.1038/bmt.2013.178.

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, cermak J, Del Canizo C Blood. 2013; 122(17):2943-64.

PMID: 23980065 PMC: 3811170. DOI: 10.1182/blood-2013-03-492884.

References

Arnoulet C, Bene M, Durrieu F, Feuillard J, Fossat C, Husson B . Four- and five-color flow cytometry analysis of leukocyte differentiation pathways in normal bone marrow: a reference document based on a systematic approach by the GTLLF and GEIL. Cytometry B Clin Cytom. 2009; 78(1):4-10. DOI: 10.1002/cyto.b.20484. View

Haferlach C, Rieder H, Lillington D, Dastugue N, Hagemeijer A, Harbott J . Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes Chromosomes Cancer. 2007; 46(5):494-9. DOI: 10.1002/gcc.20433. View

Marin D, Milojkovic D, Olavarria E, Khorashad J, de Lavallade H, Reid A . European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008; 112(12):4437-44. PMC: 6143157. DOI: 10.1182/blood-2008-06-162388. View

Muller M, Cross N, Erben P, Schenk T, Hanfstein B, Ernst T . Harmonization of molecular monitoring of CML therapy in Europe. Leukemia. 2009; 23(11):1957-63. DOI: 10.1038/leu.2009.168. View

Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J . Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006; 108(1):28-37. PMC: 1895821. DOI: 10.1182/blood-2006-01-0092. View

Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M . Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011; 29(6):761-70. PMC: 4979120. DOI: 10.1200/JCO.2010.31.8436. View

Ljungman P, de la Camara R, Cordonnier C, Einsele H, Engelhard D, Reusser P . Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant. 2008; 42(4):227-40. DOI: 10.1038/bmt.2008.162. View

Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T . Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009; 115(20):4715-26. DOI: 10.1002/cncr.24531. View

Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J . Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2006; 21(1):12-7. DOI: 10.1038/sj.leu.2404441. View

10.

Buchner T, Berdel W, Haferlach C, Haferlach T, Schnittger S, Muller-Tidow C . Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol. 2008; 27(1):61-9. DOI: 10.1200/JCO.2007.15.4245. View

11.

Grimwade D, Jovanovic J, Hills R, Nugent E, Patel Y, Flora R . Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009; 27(22):3650-8. DOI: 10.1200/JCO.2008.20.1533. View

12.

Rawstron A, Villamor N, Ritgen M, Bottcher S, Ghia P, Zehnder J . International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007; 21(5):956-64. DOI: 10.1038/sj.leu.2404584. View

13.

Hehlmann R, Hochhaus A, Baccarani M . Chronic myeloid leukaemia. Lancet. 2007; 370(9584):342-50. DOI: 10.1016/S0140-6736(07)61165-9. View

14.

Staal F, Cario G, Cazzaniga G, Haferlach T, Heuser M, Hofmann W . Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks. Leukemia. 2006; 20(8):1385-92. DOI: 10.1038/sj.leu.2404274. View

15.

Dohner H, Estey E, Amadori S, Appelbaum F, Buchner T, Burnett A . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2009; 115(3):453-74. DOI: 10.1182/blood-2009-07-235358. View

16.

Branford S, Cross N, Hochhaus A, Radich J, Saglio G, Kaeda J . Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia. 2006; 20(11):1925-30. DOI: 10.1038/sj.leu.2404388. View

17.

Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J . Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27(35):6041-51. PMC: 4979100. DOI: 10.1200/JCO.2009.25.0779. View

18.

Saussele S, Lauseker M, Gratwohl A, Beelen D, Bunjes D, Schwerdtfeger R . Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood. 2009; 115(10):1880-5. DOI: 10.1182/blood-2009-08-237115. View

19.

Haferlach T, Kohlmann A, Wieczorek L, Basso G, Te Kronnie G, Bene M . Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010; 28(15):2529-37. PMC: 5569671. DOI: 10.1200/JCO.2009.23.4732. View

20.

Ljungman P, Engelhard D, de la Camara R, Einsele H, Locasciulli A, Martino R . Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant. 2005; 35(8):737-46. DOI: 10.1038/sj.bmt.1704870. View